Advanced Filters
noise
Found 64,920 clinical trials
D Darius Ebrahimi-Fakhari, MD, PhD

Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia

The Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP) is focused on gathering longitudinal clinical data as well as biological samples (skin and/or blood and/or saliva) from male or female patients who exhibited onset of HSP symptoms at 18 years old or younger with (1) a …

30 years of age All Phase N/A
A Ariadna B Łada-Maśko, M.A.

The Role of Family and Individual Factors in Going Through Adolescence - Perspective of a Healthy Child.

The goal of this observational study is to investigate the specificity of the growing up process in young people with disabled siblings. The functioning of adolescents with disabled siblings as a person growing up in three environments will be examined: family, peers and school. The main questions it aims to …

16 - 18 years of age All Phase N/A

Hypercalcemia After Paraffin Oil Injection

Today, there is an increased use of non-medical, invasive cosmetic treatments globally without sufficient awareness of possible health risks. A particular problem is young men injecting large amounts of paraffin oil into skeletal muscles especially on upper arms and chest to increase the visible size of the muscles. Several case …

18 - 80 years of age Male Phase N/A
V Veli-Jukka Anttila, MD, Docent

Immune Responses in Health Care Personnel

This is an investigator-initiated 10 year long open cohort observational study, aiming to increase the understanding of the humoral and cellular immunological mechanisms of vaccination against influenza, including effects of repeated vaccination, the duration of protection, immunity against circulating viruses, as well as factors affecting the immunological responses and immunity …

18 - 64 years of age All Phase N/A
D Daniel Kleissler

Young Adult Infusion Space Experience Satisfaction Survey

The purpose of this study is to compare the satisfaction of Adolescent and Young Adults (AYA) receiving treatment in two different infusion spaces at the North Carolina Basnight Cancer Hospital (NCBCH). A survey and semi-structured interviews will be administered to participants to compare the experience with the built environment, with …

18 - 39 years of age All Phase N/A
F Forthoffer Natacha

Prevalence of Cognitive Disorders in Newly Diagnosed Epilepsy

A prospective prevalence study recorded that up to 50% of adult patients with newly diagnosed epilepsy had at least one cognitive impairment before initiation of antiepileptic drug (AED). Multiple factors exist and interact in the same patient. Cognitive impairments may affect psychiatric (loss of self-esteem, anxiety, depression) and social status …

16 years of age All Phase N/A
S Sarah Svenningsen, PhD

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.

40 - 85 years of age All Phase N/A
K Kirstie Lithgow, MD

68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging [including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available]

18 - 100 years of age All Phase N/A
X Xueqin Yang, PH.D.

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

Investigators established the efficacy evaluation criteria for tumor markers (RecistTM) in the preliminary research. Among patients with advanced non-small cell lung cancer, patients with positive driving genes are more likely to exhibit abnormalities in tumor markers, which suggests that this criteria may be more suitable for evaluating the efficacy of …

18 years of age All Phase N/A
G Giorgia Coratti, PhD

MAP THE SMA: a Machine-learning Based Algorithm to Predict THErapeutic Response in Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA) is caused by the homozygous loss of the Survival Motor Neuron (SMN) 1 gene, which leads to degeneration of spinal alpha-motor neurons and muscle atrophy. Three treatments have been approved for SMA but the available data show interpatient variability in therapy response and, to date, individual …

years of age All Phase N/A

Simplify language using AI